$AVXL

Anavex Life Sciences (AVXL) is advancing Alzheimer's Phase 3 planning with the FDA and reported $118.3M in cash, extending its runway into fiscal 2028. The company is focusing on blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome. It expects to submit a Fragile X IND in September and seeks FDA agreement to include pediatric patients in its Rett syndrome Phase 3 trial.

Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.

Anavex Life Sciences (AVXL) reported Q3 2026 net income of $7.8M, reversing a prior-year loss, driven by expense recoveries. Cash reserves total $118.3M. The company advanced its lead drug, Blarcamesine, in Alzheimer's, Rett, and Fragile X trials, with FDA discussions planned.

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s

Anavex Life Sciences (NASDAQ:AVXL) filed definitive proxy materials for a Sept. 24, 2026 annual meeting, where a contested board election will pit Anavex’s six nominees against PVG Asset Management’s slate. Anavex says PVG holds 0.35%. The vote coincides with FDA engagement on blarcamesine in Alzheimer’s and Rett, plus Fragile X, and a Nasdaq delinquency over a late March 10-Q.

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease New York, NY, July 30, 2026 - Anavex Life Sciences Corp. (A

The Second Circuit affirmed dismissal of a securities fraud suit against Anavex Life Sciences Corp. in Huey v. Anavex, ruling the plaintiff failed to plausibly plead loss causation. The stock rose 5.8% on the corrective disclosure day, then fell 7.0% and 4.8% over two days, tracking the broader market, according to the court.

Anavex Life Sciences announced new scientific findings linking autism spectrum disorder (ASD) and Alzheimer’s disease (AD) through shared biological mechanisms like autophagy dysfunction and synaptic pruning deficits. The company cites epidemiological research indicating autistic adults may have up to 8 times higher dementia rates. These findings support Anavex's intent to advance blarcamesine, a SIGMAR1 activator, into pivotal clinical studies, building on its demonstrated effects in previous trials for Alzheimer's, Rett syndrome, and Parkinson's disease dementia.

Anavex Life Sciences Corp. announced that its President & CEO, Christopher U Missling, PhD, will present at the Citizens Life Sciences Conference on March 10, 2026, at 11:55 AM (ET). The company is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for various neurological disorders including Alzheimer's disease and Parkinson's disease. Anavex highlights its lead drug candidate, ANAVEX®2-73 (blarcamesine), which has undergone several clinical trials for Alzheimer's, Parkinson's, and Rett syndrome, and also mentions ANAVEX®3-71 for Alzheimer's disease.

Anavex Life Sciences (Nasdaq: AVXL) CEO, Christopher U Missling, PhD, is scheduled to present at the Citizens Life Sciences Conference on Tuesday, March 10, 2026, at 11:55 AM ET. The presentation will cover the company's clinical-stage CNS programs, including therapies for Alzheimer's, Parkinson's, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases. This event is part of Anavex's ongoing investor relations efforts to increase awareness of its pipeline.